Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimers Disease: early-phase trial registry
35 of 150 indexed Alzheimers Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #78 of 28,707 conditions by registered trial count.
150 US clinical trials · 35 currently recruiting · #78 of 28,707 conditions by registered trial count
Alzheimers Disease: 150 US clinical trials tracked, 35 recruiting.
Alzheimers Disease is the subject of 150 registered US clinical trials on ClinicalTrials.gov, 35 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 76 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 8 of these trials.
Enrollment posture brief
Registry condition alzheimers-disease
OPEN 35 | RECR 23% | LATE 25 | EARLY 76 | RANK #78 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus (23% recruiting · 210 trials)
Alzheimers Disease lists 35 open slots (23% of 150 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimers Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimers Disease is recruiting below its size-band peers.
35 of 150 indexed trials (23.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimers Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 8 of 150 trials (5.3%). 90 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimers Disease enrolment sits around 105 participants.
Median target enrolment is 105 among the 148 trials that report a genuine target (sentinel values excluded). 70 of those (47.3%) plan for fewer than 100 participants.
-
Alzheimers Disease research is mostly interventional.
123 interventional and 27 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
150 total, page 2 of 3
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
Eisai
NCT00478205
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Eli Lilly and Company
NCT00762411
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
H. Lundbeck A/S
NCT01955161
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
Eisai
NCT00566501
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
GlaxoSmithKline
NCT00428090
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
TauRx Therapeutics
NCT01689233
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
GlaxoSmithKline
NCT00710684
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00151502
Diagnosis and Natural History Study of Patients With Neurological Conditions
National Institute of Neurological Disorders and Stroke (NINDS)
NCT00001549
A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy
Hoffmann-La Roche
NCT01677754
Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)
University of Washington
NCT01708304
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
AbbVie
NCT02880956
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Otsuka Pharmaceutical Development & Commercialization
NCT01862640
fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease
University of Wisconsin, Madison
NCT00478491
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Hoffmann-La Roche
NCT02051608
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Targacept
NCT01466088
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
Teva Branded Pharmaceutical Products R&D
NCT00104273
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
GE Healthcare
NCT01028053
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Instituto Grifols, S.A.
NCT01561053
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
Alzheimer's Disease Cooperative Study (ADCS)
NCT01078636
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Saegis Pharmaceuticals
NCT00093951
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
AbbVie (prior sponsor, Abbott)
NCT00948909
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization
NCT01922258
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization
NCT03594123
Home Safety Clinical Trial for Alzheimer's Disease
US Department of Veterans Affairs
NCT00459355
AAB-001 in Patients With Mild to Moderate Alzheimer's Disease
JANSSEN Alzheimer Immunotherapy Research & Development
NCT00112073
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
Eisai
NCT00096473
Care Management for Patients With Alzheimer Disease and Their Family Caregivers
Agency for Healthcare Research and Quality (AHRQ)
NCT00246896
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
Bristol-Myers Squibb
NCT00810147
Posterior Cingulate Function in Persons With Risk Factors for Alzheimer's Disease
University of Wisconsin, Madison
NCT00478166
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
Pamlab
NCT01370954
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
Eli Lilly and Company
NCT00051909
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
National Institute of Mental Health (NIMH)
NCT00955422
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
Novartis Pharmaceuticals
NCT01097096
Efficacy of Early Stage Alzheimer's Support Groups
University of Washington
NCT00391794
iCare Stress Management e-Training for Dementia Family Caregivers
Photozig
NCT01378195
Brain Imaging in Elderly People and Individuals With Alzheimer's Disease
National Institute of Mental Health (NIMH)
NCT00001917
Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention
NYU Langone Health
NCT02347202
Enhancing Quality of Life for Nursing Home Residents
Penn State University
NCT00388544
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia
Otsuka Pharmaceutical Development & Commercialization
NCT00095719
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
Pamlab
NCT01745198
High Intensity Light Therapy in Alzheimer's Disease
National Center for Complementary and Integrative Health (NCCIH)
NCT00065689
Dose Response Study of Aerobic Exercise in Older Adults
Jeff Burns, MD
NCT01129115
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
Icahn School of Medicine at Mount Sinai
NCT04666077
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
Neumora Therapeutics
NCT06546995
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
Mayo Clinic
NCT01607476
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
VA Office of Research and Development
NCT02350127
Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147
Abrexa Pharmaceuticals
NCT03838185
VI-1121 for the Treatment Alzheimer's Disease
VIVUS
NCT01428362
Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly
Cerecin
NCT00660088
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 39 |
| Phase 3 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimers Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimers Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimers Disease page
150 registered trials, 35 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 35 Alzheimers Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimers Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimers Disease condition card totals 150 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.